1. Introduction {#sec1}
===============

Three apparently distinct disorders involving retrograde degeneration of the upper motor neurons of the pyramidal tracts seem to be caused by mutations in the ALS2 gene, which provides instructions for making a protein called Alsin. They comprise a clinical continuum from infantile ascending hereditary spastic paraplegia (IAHSP) (OMIM number 607225), to juvenile forms without lower motor neuron involvement, namely, juvenile primary lateral sclerosis (JJPLS) (OMIM number 606353), and to forms with lower motor neuron involvement, namely, autosomal recessive juvenile amyotrophic lateral sclerosis (JALS) (OMIM number 205100) \[[@B1], [@B2]\]. There is no available data on the prevalence of ALS2 related disorders. However, they are probably currently underdiagnosed, even if they have been described in individuals from a variety of ethnic backgrounds, mainly from the Mediterranean \[[@B1]\].

All the patients are homozygous or heterozygous compounds for ALS2 mutations \[[@B1]\]. To date, a total of 45 patients with known mutations in the ALS2 gene have been described, but the phenotype-genotype correlation remains unclear \[[@B2]\]. In the present study, we describe the clinical and genetic features of a 16-year-old boy with IAHSP from Northern Portugal ([Table 1](#tab1){ref-type="table"}).

2. Case Report {#sec2}
==============

The patient was born after a twin pregnancy from nonconsanguineous parents and the pregnancy included maternal hemorrhage in the second trimester. Delivery was at the 36th week of gestation by Cesarean section. The twins were dizygotic twins and the patient\'s twin sibling is healthy. His 42-year-old mother is healthy and his father died at the age of 35 after a car accident, without any signs of a neurological disorder. The boy acquired cephalic control at three months and started to sit unaided at six months, crawl at nine months, and walk with support at 10 to 11 months. Stiffness of the lower limbs and tiptoeing with hyperactive deep tendon reflexes were noticed at the age of three and scissoring gait started during his fourth year. He was never able to walk without support and underwent Achilles tenotomy at the ages of three and five. An ascending progression of motor difficulties was observed, with spasticity becoming evident in the upper extremities after the age of six. Muscle atrophy in the lower limbs was evident after the age of seven and he was wheelchair bound at the age of eight. Sphincter incontinence started at the same time and he developed supranuclear bulbar palsy, with progressive dysarthria. MRI, electromyography, and nerve conduction studies at that age were normal. Anarthria was evident at the age of 13. At the age of 14, there was clinical worsening and since then he has had bilateral limitation of horizontal eye movements, dysphagia when drinking liquids, chewing difficulties, severe drooling, and paroxysms of laughter. Cognitive function is still normal at the age of 16.

3. Material and Methods {#sec3}
=======================

DNA was extracted from a peripheral blood sample from the patient, his mother, and twin brother. All 34 exons of the ALS2 gene were analysed by PCR and sequencing of both DNA strands of the entire coding region was carried out, including the highly conserved exon-intron splice junctions.

We also reviewed all cases of ALS2 related disorders with known ALS2 gene mutations and detailed clinical, neurophysiological, and imaging data that have so far been reported in PubMed. Continuous variables with asymmetric distribution are described by medians (minimum to maximum) and categorical variables are described by absolute and relative frequencies. To compare the three phenotypes (IAHSP, JALS, and JPLS) we used the Kruskal-Wallis test if the variables were continuous and the Monte Carlo test if they were categorical. The statistical analysis was performed using SPSS v.20 (IBM, USA) and *P* values of less than 0.05 were considered significantly different.

4. Results and Discussion {#sec4}
=========================

Our patient displays a clinical picture that is highly suggestive of ALS2 related disorder. This case study presents evidence of previously unreported heterozygous variants in exon 5 (c.1425_1428del p.G477Afs\*19) and exon 3 (c.145G\>A p.G49R).

To date, case studies of 45 patients with ALS mutations have been reported. Four patients with JALS were excluded because a detailed clinical description was not available \[[@B3]\]. The clinical characteristics and neurophysiological and imaging studies of the remaining 41 cases, plus our case study, are summarized in [Table 2](#tab2){ref-type="table"}. Of these, 21 (50%) of the patients were classified as having an IAHSP phenotype, 17 (40.5%) had a JALS phenotype, and four (9.5%) had a JPLS phenotype. Median age at onset of walking loss, upper limb involvement, speech impairment, and becoming wheelchair bound was similar between the three groups.

The heterozygous variant in exon 5 (c.1425_1428del p.G477Afs\*19) creates a shift in the reading frame, starting at codon 477. The new reading frame ends in a stop codon 18 positions downstream, which is very likely to result in truncated protein or loss of protein production. Therefore, it is very likely to be a disease causing mutation. A small deletion in this region (c.1427_1428delAG), which also causes a frameshift, has previously been described as disease causing for ALS2 \[[@B4]\]. The other unreported heterozygous variant was found in exon 3 (c.145G\>A p.G49R), which is located in a moderately conserved amino acid, with moderate physiochemical differences between the amino acids glycine and arginine. Polyphen-2, SIFT, and MutationTaster predict that this variant is probably damaging. This variant in exon 3 was also found in our patient\'s twin brother and their mother, who were both healthy. It was impossible to test his father because he was dead.

Despite the limited number of patients reported in the literature with known ALS2 mutations and considering the bias related to the age, the majority of clinical characteristics were similar between both groups. Because all the families reported to date have had different ALS2 mutations, it is impossible to draw any genotype-phenotype correlation.

5. Conclusions {#sec5}
==============

Despite the limited information about clinical characteristics, patients with IAHSP, JALS, and JPLS may present with different phenotypes that overlap.
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###### 

Mutations in ALS2 related disorders.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Exon/intron        Mutation          Predicted protein   Phenotypic classification   References
  --------- ------------------ ----------------- ------------------- --------------------------- ----------------------------------------------
  1         Intron 24          c.3836+1G\>T      p.k1234fs∗3         IAHSP                       Racis et al., 2014 \[[@B5]\]

                                                                                                 

  2         Intron 9           c.2000-2A\>T      p.E724fs∗32         IAHSP                       Herzfeld et al., 2009 \[[@B6]\]

                                                                                                 

  3         Exon 9             c.1825_1826ins5   p.E609fs∗9          IAHSP                       Sztriha et al., 2008 \[[@B7]\]

  4         Exon 13            c.2529G\>T        p.G1177∗            IAHSP                       

                                                                                                 

  5, 6      Exon 10            c.2143C\>T        p.Q715∗             IAHSP                       Verschuuren-Bemelmans et al., 2008 \[[@B8]\]

                                                                                                 

  7, 8      Exon 4             c.467G\>A         p.C156Y             IAHSP                       Eymard-Pierre et al., 2006 \[[@B9]\]

                                                                                                 

  9, 10     Exon 18            c.2992C\>T        p.R998∗             IAHSP                       Devon et al., 2003 \[[@B10]\]

                                                                                                 

  11        Exon 32            c.4844delT        p.I331fs335         IAHSP                       Gros-Louis et al., 2003 \[[@B11]\]

                                                                                                 

  12--17    Exon 4             c.1130delAT       p.I331fs335         IAHSP                       Eymard-Pierre et al., 2002 \[[@B12]\]

  Exon 13   c.2660delAT        p.N845fs858       IAHSP                                           

  Exon 6    c.1471_1480del10   p.V491Gfs∗3       IAHSP                                           

  Exon 22   c.3742delA         p.M1206∗          IAHSP                                           

                                                                                                 

  18--20    Exon 5             C.1548delAG       p.T475Tfs∗70        IAHSP                       Hadano et al., 2001 \[[@B4]\]

                                                                                                 

  21        Exon 5\            c.1427_1428del\   p.G477Afs∗19\       IAHSP                       Our study
            Exon 3             c.145G\>A         p.G49R                                          

                                                                                                 

  22-23     Exon 4\            c.299G\>T\        p.S100I             JALS\                       Luigetti et al., 2013 \[[@B13]\]
            Exon 14            c.2580-2A\>G                          JALS                        

                                                                                                 

  24-25     Exon 22            c.3565delG        p.V1189WfsX19       JALS                        Shirakawa et al., 2009 \[[@B2]\]

                                                                                                 

  26        Exon 4             c.553delA         p.T185LfsX5         JALS                        Kress et al., 2005 \[[@B14]\]

                                                                                                 

  27--38    Exon 3             c.138delA         p.A46AfsX5          JALS                        Hadano et al., 2001 \[[@B4]\]

                                                                                                 

  39--41    Intron 17          c.2980-A\>G       p.T993fs∗7          JPLS                        Mintchev et al., 2009 \[[@B15]\]

                                                                                                 

  42        Exon 6             c.1619G           p.G540E             JPLS                        Panzeri et al., 2006 \[[@B16]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of the characteristics of 42 patients with known ALS2 gene mutations.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Age    Origin            Motor development by 1 year   Age at onset   Loss of walking   Upper limb involvement   Bulbar involvement   Speech impairment                       Ocular movements   Wheelchair bound   EMG   Evoked potentials       Brain imaging   Phenotypic classification   References
  --------- ------ ----------------- ----------------------------- -------------- ----------------- ------------------------ -------------------- --------------------------------------- ------------------ ------------------ ----- ----------------------- --------------- --------------------------- ----------------------------------------------
  1         17 y   Italy             Ab                            12 mo          NA                8 y                      8 y                  Disarthria at 8 y, Anarthria at 11 y                       8 y                Ab    SSEP ab                 Ab              IAHSP                       Racis et al., 2014 \[[@B5]\]

                                                                                                                                                                                                                                                                                                          

  2         7 y    Germany           Ab                            18 mo          \<7 y             \<7 y                    7 y                                                          N                  7 y                                              Ab              IAHSP                       Herzfeld et al., 2009 \[[@B6]\]

                                                                                                                                                                                                                                                                                                          

  3         11 y   Hungary           Ab                            10 mo          NA                2 y                      5 y                  No                                      N                  11 y               N     Motor ab                N               IAHSP                       Sztriha et al., 2008 \[[@B7]\]

  4         6 y    Hungary           Ab                            \<1 y          NA                No                       5 y                  No                                      N                  5 y                                              N               IAHSP                       

                                                                                                                                                                                                                                                                                                          

  5         13 y   The Netherlands   Ab                            8 mo           NA                3 y                      5 y                  Anarthria at 13 y                       N                  13 y               N     MEP Unobtainable        N               IAHSP                       Verschuuren-Bemelmans et al., 2008 \[[@B8]\]

  6         8 y    The Netherlands   Grossly N                     18 mo          NA                Yes                      4 y                  No                                      N                  No                 N     MEP Unobtainable        N               IAHSP                       

                                                                                                                                                                                                                                                                                                          

  7         22 y   Turkey            Ab                            1 y            12 y              12 y                     16 y                 No                                                         12 y                                                             IAHSP                       Eymard-Pierre et al., 2006 \[[@B9]\]

  8         20 y   Turkey            Ab                            1 y            10 y                                       12 y                 No                                                         10 y               N     Motor ab                Ab              IAHSP                       

                                                                                                                                                                                                                                                                                                          

  9         9 y    Bukhari Jewish    N                             1-2 y          NA                2 y                      3 y                  Dysarthria at 9 y                                          No                                                               IAHSP                       Devon et al., 2003 \[[@B10]\]

  10        6 y    Bukhari Jewish    N                             14 mo          6 y               6 y                      6 y                  Dysarthria at 6 y                                          No                 N                             N               IAHSP                       

                                                                                                                                                                                                                                                                                                          

  11        12 y   Pakistan          Ab                            18 mo          12 y                                       \<12 y               Anarthria at 12 y                                          12 y                                                             IAHSP                       Gros-Louis et al., 2003 \[[@B11]\]

                                                                                                                                                                                                                                                                                                          

  12        36 y   Algeria                                         1 y            NA                \<7 y                    13 y                 Dysarthria at 13 y                      N                                     N     MEP and SSEP abnormal   Ab              IAHSP                        \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                           \
                                                                                                                                                                                                                                                                                                          Eymard-Pierre et al., 2002 \[[@B12]\]

  13        31 y   Algeria                                         1 y            NA                \<7 y                    13 y                 Dysarthria at 13 y                      N                                     N     MEP and SSEP abnormal                   IAHSP                       

  14        24 y   Algeria                                         1 y            NA                \<7 y                    13 y                 Dysarthria at 13 y                      N                                     N     MEP and SSEP abnormal                   IAHSP                       

  15        18 y   France                                          1.5 y          4 y               6 y                      8 y                  Dysarthria at 4 y, anarthria at 12 y    Ab                                    N     MEP and SSEP abnormal   Ab              IAHSP                       

  16        23 y   Italy                                           1.4 y          5 y               10 y                     12 y                 Dysarthria at 10 y, anarthria at 16 y   Ab                                    N     MEP and SSEP abnormal   Ab              IAHSP                       

  17        20 y   Italy                                           1.5 y          4 y               9 y                      13 y                 Dysarthria at 11 y, anarthria at 18 y   Ab                                    N     MEP and SSEP abnormal   Ab              IAHSP                       

                                                                                                                                                                                                                                                                                                          

  18        14 y   Kuwait            N                             14 mo          2 y               9 y                      4 y                  Dysarthria at 4 y, anarthria at 14 y                                          N     N                       Ab              IAHSP                       Hadano et al., 2001 \[[@B4]\]

  19        6 y    Kuwait            Ab                            11 mo          NA                                         5 y                  Dysarthria at 5 y,                      N                  No                                               Ab              IAHSP                       

  20        2 y    Kuwait            Ab                            9 mo           NA                                                                                                                                                                                          IAHSP                       

                                                                                                                                                                                                                                                                                                          

  21        16 y   Portugal          N                             3 y            NA                6 y                      8 y                  Dysarthria at 8 y, anarthria at 13 y    Ab                 8 y                N                             N               IAHSP                       Our study

                                                                                                                                                                                                                                                                                                          

  22        27 y   Italy             N                             3 y                                                                            Dysarthria at 7 y, anarthria at 14 y                                          Ab    SSEP N                  N               JALS                        Luigetti et al., 2013 \[[@B13]\]

  23        21 y   Italy             N                             6 y                                                                                                                                                          Ab    SSEP N                  N               JALS                        

                                                                                                                                                                                                                                                                                                          

  24        32 y   Japan             N                             13 mo          No                                         11 y                 Dysarthria at 11 y, anarthria at 14 y                      No                 Ab                            N               JALS                        Shirakawa et al., 2009 \[[@B2]\]

  25        23 y   Japan             N                             3 y            No                                                              Dysarthria                                                 No                                                               JALS                        

                                                                                                                                                                                                                                                                                                          

  26        32 y   Turkey            Ab                            22 mo          16 y              12 y                     15 y                 18 y                                                       16 y               Ab    Motor ab, SSEP N                        JALS                        Kress et al., 2005 \[[@B14]\]

                                                                                                                                                                                                                                                                                                          

  27        60 y   Tunisia           N                             10 y                                                      10 y                                                                                               N     Motor N                                 JALS                        Hadano et al., 2001 \[[@B4]\]

  28        36 y   Tunisia           N                             6.5 y                                                     6.5 y                                                                                              N                                             JALS                        

  29        27 y   Tunisia           N                             3.5 y                                                     Yes                                                                                                N     Motor N, SSEP ab                        JALS                        

  30        22 y   Tunisia           N                             6.5 y                                                     6.5 y                                                                                              N     Motor N                                 JALS                        

  31        21 y   Tunisia           N                             9 y                                                       9 y                                                                                                N                                             JALS                        

  32        14 y   Tunisia           N                             6.5 y                                                     6.5 y                                                                                              N                                             JALS                        

  33        23 y   Tunisia           N                             6.5 y                                                     6.5 y                                                                                              N     Motor N                                 JALS                        

  34        28 y   Tunisia           N                             3.5 y                                                     Yes                                                                                                N                                             JALS                        

  35        32 y   Tunisia           N                             7.5 y                                                     Yes                                                                                                N     Motor N                                 JALS                        

  36        22 y   Tunisia           N                             6.5 y                                                     Yes                                                                                                N                                             JALS                        

  37        21 y   Tunisia           N                             10 y                                                      Yes                                                                                                N     Motor N, SSEP ab                        JALS                        

  38        7 y    Tunisia           N                             6 y                                                       Yes                                                                                                N                                             JALS                        

                                                                                                                                                                                                                                                                                                          

  39        55 y   Cyprus            N                             2 y            50 y              Yes                      3 y                                                          Ab                 50 y                                                             JPLS                        Mintchev et al., 2009 \[[@B15]\]

  40        42 y   Cyprus            N                             2 y            2 y               Yes                      2 y                                                          Ab                 2 y                      SSEP N                  N               JPLS                        

  41        16 y   Cyprus            N                             2 y            No                Yes                      2 y                                                          Ab                 No                 Ab                                            JPLS                        

                                                                                                                                                                                                                                                                                                          

  42        34 y   Italy             N                             2 y            19 y              2 y                      6 y                  Dysarthria at 6 y, anarthria at 20 y    Ab                 34 y               Ab    Motor ab                N               JPLS                        Panzeri et al., 2006 \[[@B16]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EMG: electromyography; N: normal; Ab: abnormal; NA: not achieved; y: years; mo: months; MEP: motor evoked potentials; SSEP: somatosensory evoked potentials.

[^1]: Academic Editor: Patrick Morrison
